Residual tumour size to predict progression in paediatric LGG (v1)

  • Research type

    Research Study

  • Full title

    Residual tumour size as a predictor of progression for pediatric low-grade glioma

  • IRAS ID

    207508

  • Contact name

    Jenny Adamski

  • Contact email

    jenny.adamski@bch.nhs.uk

  • Sponsor organisation

    Birmingham Children's Hospital

  • Duration of Study in the UK

    0 years, 2 months, 31 days

  • Research summary

    Low grade gliomas (LGG) account for 35% of all paediatric brain tumours. They are benign tumours made up of different subtypes and clinical features. They have a very good overall prognosis with low likelihood of disease progression in adulthood. In children however, recurrence or progression may occur causing clinical symptoms and requiring further treatment, particularly if the tumour is not completely removed. Often surgery does not achieve a complete removal as the tumour is close to vital central nervous system structures. Therefore a residual tumour is left, which is documented by imaging after surgery. In a considerable proportion of these children (45-65%) further growth occurs and further treatment is required. If the tumour is completely removed however, recurrence is rare. All children need to be followed-up with imaging at regular intervals to detect recurrence. This is a considerable burden on families and requires significant resources. There is a lack of evidence as to the features of a tumour that can predict recurrence or progression. This study aims to retrospectively look at children with a diagnosis of low-grade glioma, treated at Birmingham Children’s Hospital, and study the clinical and imaging characteristics to determine possible predictors of disease relapse and progression. Data will be analysed to detect a cut-off residual tumour size that can predict tumour progression. The timing of any progression from initial surgery will also be determined. From these, a guideline for surveillance imaging will be produced, suggesting the optimal frequency of scanning based on a patient's risk of recurrence.

  • REC name

    Wales REC 4

  • REC reference

    16/WA/0168

  • Date of REC Opinion

    3 Jun 2016

  • REC opinion

    Favourable Opinion